N itric oxide (NO) plays an important role in the regulation of redox signaling and cellular function. [1] [2] [3] NO can be generated by NO synthase (NOS) or by the breakdown of nitrite or other compounds to NO. 4 -6 NOS catalyzes the synthesis of NO by the conversion of L-arginine and oxygen to L-citrulline and NO, in the presence of NADPH and tetrahydrobiopterin. Both endothelial NOS (eNOS) and neuronal NOS (nNOS) are constitutively expressed in distinct subcellular locations within cardiomyocytes: eNOS is generally thought to be predominantly localized to invaginations of the sarcolemma called caveolae 7, 8 and nNOS is mostly found in the sarcoplasmic reticulum (SR). 8, 9 However, changes of expression and redistribution of these two constitutive isoforms of NOS have been found in some disease conditions such as myocardial infarction 10, 11 and heart failure. 12 The third isoform of NOS, the inducible NOS (iNOS), is barely detected in the myocardium under normal conditions, but expression of iNOS is stimulated by inflammatory mediators. 13, 14 A mitochondrial NOS has been reported to be present in the inner mitochondrial membrane or matrix, 15 although there are conflicting results regarding mitochondrial NOS. 16 -19 An alternative source of mitochondrial NO could be nNOS associated with the SR, as the SR membrane has been shown to be attached to the outer mitochondrial membrane. 20 -22 This differential NOS localization provides organelle or subcellular generation of NO, which in turn provides a localized signal for protein S-nitrosylation. 23, 24 In addition to activating cGMP-dependent signaling pathways, recent studies suggest that NO, by attachment of an NO moiety to a nucleophilic protein sulfhydryl resulting in S-nitrosothiol (SNO) formation, generates a posttranslational modification known as protein S-nitrosylation, which plays an important role in biology. 25, 26 Recent data suggest that protein SNO is important in cardioprotection. This review focuses on the role of S-nitrosylation in cardioprotection and the potential mechanism(s) involved.
NO and Ischemia/Reperfusion Injury

NO Is Generated During Ischemia/Reperfusion
A number of studies have shown that NO is produced during ischemia. 4, [27] [28] [29] The NO that is generated appears to be attributable to both NOS-dependent and NOS-independent pathways. During ischemia, when oxygen is low, nitrite conversion into NO is likely to be an important source of NO. However there is likely to be some residual oxygen, particularly at the beginning of ischemia, and Zweier et al have shown that with short durations of ischemia (30 minutes ) N G -nitro-L-arginine methyl ester (L-NAME), a NOS inhibitor, blocks approximately 60% to 80% of NO generation. 27 Thus, it appears that both NOS-dependent and -independent (nitrite) mechanisms are involved in the generation of NO during ischemia. The exact proportion of NOS dependent and independent NO generation may depend on the model (the duration of ischemia, the diet, and the species). These data show that NO is generated during ischemia, which raised the question of whether the NO generated during ischemia is beneficial or detrimental?
Increasing NO Protects
Addition of NO donors, particularly at concentrations that release NO at physiological (submicromolar) levels, has been shown to reduce ischemia/reperfusion (I/R) injury. 30, 31 Similarly, cardiac-specific overexpression of eNOS 32, 33 or iNOS 34 has been reported to reduce I/R injury. Thus, there is reasonable agreement that a slight increase in NO is cardioprotective. Consistent with a protective role for NO, a number of cardioprotective models have been shown to involve an increase in NOS. 35 For example, protection in females 36, 37 and erythropoietin-mediated protection 38, 39 require NOS activation. Also, in models of I/R injury in various tissues, such as heart and liver, nitrite has been shown to reduce infarct size and to reduce apoptosis and necrosis. 5, 6 The mechanism of nitrite-mediated cytoprotection appears to be NO-dependent, because a loss of cytoprotection occurred when animals were treated with an NO scavenger. 5, 6 
Reducing NO Below Basal Levels Has No Consistent Effect on Protection
Whether loss or inhibition of NOS exacerbates I/R injury has been controversial, especially the data involving eNOS knockout (eNOS-KO) mice. Studies comparing infarct size after I/R in wild type (WT) and eNOS-KO hearts report no difference, 40 -42 a reduction 43 and an increase in infarct size. 43, 44 Part, but not all, of the discrepancy appears to be related to two different models of eNOS-KO mice. Lefer and colleagues 43 studied I/R in the eNOS-KO mice generated at Harvard compared to those generated at University of North Carolina (UNC). They found an 84% increase in infarct size in the Harvard eNOS-KO mice, but a decrease in infarct size in the UNC eNOS-KO mice. This difference was attributed to a compensatory increase in iNOS in the UNC eNOS-KO mice, which resulted in protection in these mice. 43 However, Guo et al 42 also examined I/R injury in both of these mouse models and, in contrast to the study by Lefer and colleagues, reported no difference in infarct size in either UNC or Harvard eNOS-KO hearts compared to WT hearts. It is possible that the induction of iNOS in the UNC mice might depend on the housing and feeding conditions of the mice, and this might account for some of the differences observed. Most studies of infarct size show no difference between WT and nNOS knockout (nNOS-KO) hearts. 44, 45 Most recent studies find that NOS inhibition does not alter infarct size or recovery of function following I/R. 42, 46, 47 However, there are some older reports showing that NOS inhibition can be protective. 27, 48, 49 NO can combine with reactive oxygen species (ROS) to generate peroxynitrite which can be detrimental particularly at high levels. 50, 51 This discrepancy between the beneficial and detrimental effects of NO might depend on the relative availability of NO versus ROS. NOS can also become "uncoupled" resulting in the generation of ROS and this might also complicate the interpretation of the effects of NOS inhibitors. Thus, the effect of NOS inhibition is variable and might depend on the level of oxidative stress. Taken together, the data suggest that, under most conditions, an increase in NO above a threshold level, as might occur with NO donors or overexpression of NOS, is protective; however lowering NO below basal levels does not appear to increase injury.
NO and Cardioprotection
As mentioned above, a slight increase in NO has been shown to be cardioprotective. Cardioprotection can be initiated acutely by activation of signaling pathways (acute protection) or by upregulation of new proteins (delayed protection), and NO has been shown to be important in both models. For simplicity we will discuss these separately and focus on acute protection. Acute protection can be initiated by signaling pathways activated before and during ischemia, ie, preconditioning (PC), as well as pathways activated at reperfusion, such as postconditioning.
NO and Acute PC
Brief episodes of ischemia and reperfusion, ie, PC, render the heart more resistant to subsequent prolonged periods of ischemia. 52 PC has been shown to lead to an increase in NO and inhibitors of PC such as inhibitors of the phosphatidylinositol 3-kinase pathway block the increase in NO production. [53] [54] [55] Inhibitors of NOS have been shown to block protection in a number of different cardioprotective models. As discussed below, inhibitors of NOS block protection associated with delayed PC and postconditioning. Also, cardioprotection in females is blocked by inhibitors of NOS or loss of either eNOS or nNOS, 11, 56 and erythropoietinmediated protection has also been reported to be blocked by NOS inhibitors. 57 The ability of NOS inhibition or loss of NOS to block acute PC, however, has resulted in discrepant results. Some, 58, 59 but not all, 60, 61 studies find that NOS inhibitors block acute PC. Interestingly, although Downey and colleagues initially reported that NOS inhibitors do not block acute PC, 60 Cohen, Downey, and colleagues 54 recently reported that the ability of L-NAME to block PC depends on the relative contribution of signaling through the adenosine pathways compared to the bradykinin or opioid pathways. They suggest that signaling via the adenosine pathway is not blocked by L-NAME. Downey and colleagues also reported that NOS inhibitors block bradykinin mediated protection. 62 Studies with mice lacking eNOS have also provided mixed results. Bell and Yellon reported that in eNOS-KO hearts, PC still reduced infarct size with 4 cycles of PC, but there was no reduction in infarct size with only 2 or 3 cycles. 63 However, Guo et al in a very well-established in vivo infarct model found that both Harvard and UNC eNOS-KO hearts exhibited a PC-mediated reduction in infarct size that was comparable to that observed in WT hearts, suggesting that eNOS is not necessary for acute PC. 42 So, what do we conclude regarding the role of NOS and NO in acute PC? Data consistently show that PC results in an increase in NO. However, inhibition of NOS, by either pharmacological inhibitors or genetic ablation, results in inconsistent results; in some cases, PC protection is blocked, but not in others. One explanation provided by Downey and Cohen is that L-NAME does not block under conditions in which PC signaling is predominantly via adenosine, rather than bradykinin or opioids. Another possible explanation for this discrepancy might be a differential role provided by nonenzymatic production of NO during PC. NO can be generated from nitrite under acidic conditions that occur during PC, 64 and this nonenzymatically generated NO would not be inhibited by NOS inhibitors. The levels of nitrite can vary depending on diet, thus leading to diet dependent differences in the NO that can be generated from nitrite. 65 Thus, some of the differences regarding whether NOS generated NO is required for acute PC might depend on the levels of nonenzymatically generated NO, which in turn might depend on diet. If sufficient NO is generated via nonenzymatic mechanisms, then NOS inhibitors would not be expected to block PC. This explanation might account for the more consistent role for NOS inhibitors in pharmacological PC (where there is no acidosis to generate NO nonenzymatically), and it would also be consistent with NOS inhibitors blocking after 2 or 3 cycles, but not after 4 cycles of PC. 54, 63 This hypothesis would also be consistent with a recent study reporting that dietary nitrite restores cardioprotection in eNOS-KO hearts. 65 
NO and Postconditioning
It has been shown that following a sustained period of ischemia, brief intermittent periods of ischemia and reperfusion administered at the start of reperfusion (postconditioning) reduced infarct size. 66 Tsang et al reported that postconditioning resulted in an increase in phosphorylation of eNOS and that the protective effects of postconditioning were blocked by the inhibition of the phosphatidylinositol 3-kinase with wortmannin, which blocked the subsequent eNOS phosphorylation. 67 Consistent with a role for NOS in postconditioning, Yang et al found that the NOS inhibitor L-NAME administered just before reperfusion blocked the protective effects of postconditioning. 68 In a recent study, addition of a mitochondria-targeted SNO at the start of reperfusion has also been found to be cardioprotective. 69 Thus, NO appears to be an important mediator in postconditioning.
NO and Delayed PC
As discussed, a trigger phase of brief intermittent periods of ischemia and reperfusion reduces infarct size following a subsequent sustained period of ischemia. The protection afforded by PC is lost if there is a delay between the brief intermittent episodes of ischemia and the sustained ischemia. Typically, if there is an hour or longer delay between the trigger preconditioning period and the sustained period of ischemia the protection is lost. However, a delayed protection occurs Ϸ24 hours after the PC trigger phase. In contrast to acute PC, 70 delayed PC involves alterations in gene expression. 13, 71 Interestingly it has been shown that NO generated by eNOS during the trigger phase is required for the protection that is observed 24 hours later. 53, 58, 72, 73 NO generated during the trigger phase activates a signaling cascade that leads to upregulation of iNOS, which is essential for the delayed PC. Also, the delayed PC is blocked in mice lacking eNOS. 74, 75 Furthermore, cardiomyocyte-specific overexpression of iNOS has been shown to attenuate reperfusioninduced ROS production and protect against I/R injury by preventing the mitochondrial permeability transition pore opening and cell death. 34 
Mechanism of NO Protection
Initial studies indicated that many NO mediated effects were attributable to NO activation of soluble guanylyl cyclase (sGC) and the resulting increase in cGMP. 76 However, NO can modify protein thiol groups, resulting in the formation of protein SNO, and this protein modification can also mediate effects of NO. 25, 26 Both sGC and SNO pathways have been reported to be important in cardioprotection. NO activation of sGC/cGMP/protein kinase G is reported to activate the mitochondrial K ATP channel by a mechanism that has not been elucidated but that presumably involves phosphorylation by protein kinase G. 77, 78 In support of this hypothesis,
, an inhibitor of sGC, has been found to block the bradykininmediated increase in ROS. 62 Lochner et al reported that ODQ significantly attenuated (to an intermediate level) the improved contractility that occurs in PC hearts. 58 Previous studies have shown that the cardioprotection of PC could be attenuated or abolished by antioxidants. 79 -81 Such a redox-based mechanism for cardioprotection of PC suggests that protein S-nitrosylation, a redox-reversible posttranslational protein modification, might play an important cardioprotective role in PC. 31, 82 Recent studies have clearly shown that in addition to NO activation of sGC, NO can mediate protection by S-nitrosylation and a number of studies have found S-nitrosylated proteins that appear to be important in cardioprotection (see the Table) . An increase of protein S-nitrosylation has also been found to be involved in nitritemediated cardioprotection. 64, 83 Before discussing the role of S-nitrosylation in cardioprotection, we will first briefly discuss the mechanisms involved in regulating protein S-nitrosylation with an emphasis on mechanisms that would be important in I/R and cardioprotection.
Mechanisms of Regulation of S-Nitrosylation
SNO Formation and Stabilization
Protein S-nitrosylation occurs by endogenous NO-mediated nitrosylating agents such as dinitrogen trioxide (N 2 O 3 ), by transition metal catalyzed addition of NO or by transnitrosylation from low-molecular-weight SNO, such as S-nitrosoglutathione (GSNO) or S-nitrosocysteine. 24, 84 The S-nitrosylation of cysteine residue(s) on proteins depends on the precise conditions of NO, O 2 , hydrophobicity, nucleophilicity, and redox surrounding the targeted thiol(s), which could change drastically during I/R. The actual redox state 85, 86 and ultrastructural accessibility 87 of cysteine residue(s) under low-oxygen tension, such as hypoxia and ischemia, might determine whether a particular thiol in a given protein is subjected to S-nitrosylation.
We are interested in mechanism(s) that might influence SNO in the setting of ischemia and PC. PC results in an increase in cytosolic Ca 2ϩ , which in turn activates constitutive NOS leading to an increase in NO for SNO formation. In addition, PC leads to formation of ROS and reactive nitrogen species, leading to a decreased intracellular reduced glutathione (GSH) pool, which might stabilize SNO formation by attenuating GSH-mediated trans-/denitrosylation. 88, 89 The effects of oxygen on protein S-nitrosylation are complex and difficult to predict a priori. Autoxidation of NO yields N 2 O 3 as a nitrosylating agent. This reaction is accelerated dramatically in a hydrophobic environment such as a lipid membrane. 90 ,91 PC involves intermittent ischemia and reperfusion, and reperfusion allows for generation of NO and nitrosylating agents such as N 2 O 3 . Furthermore, the stability of SNO appears to be favored by low ambient oxygen. 92 With increasing oxygen, the level of protein S-nitrosylation has been found to decrease, whereas S-thiolation is promoted, 93 and the intermediate thiyl radical is proposed to be involved in the decomposition SNO. 94 Consistent with this concept, breathing low oxygen concentrations has been found to potentiate the ability of inhaled NO to increase cardiac albumin-SNO. 95 Also, an increase of protein S-nitrosylation has been recently reported in a study of endothelial cells exposed to acute hypoxia. 96 Taken together, the intermittent reperfusion can increase generation of NO/SNO, and the formed SNO will be stabilized by the low oxygen during the sustained ischemia. On reperfusion oxygen is restored and this would accelerate the breakdown of the SNO. This concept is supported by a study in which an increase in SNO occurred during PC, whereas a decline in SNO occurred on reperfusion. 11 Thus, PC would provide an environment that might favor S-nitrosylation, including NO/SNO formation, ion content, and redox equilibrium.
Reversibility of SNO: Transnitrosylation and Denitrosylation
If SNO has a regulatory role in cell biology, it is expected that there are regulated mechanisms for removal of SNO, similar to the role of phosphatases in proteins phosphorylation. In fact, a number of mechanisms have been described leading to the removal of protein S-nitrosylation (see elsewhere 97 ). The nitrosyl moiety could be removed by transnitrosylation (ie, transfer of NO moiety between proteins) with low-molecularmass thiols, such as GSH to form GSNO, or cysteine thiols to form S-nitrosocysteine. 84 However, unless the GSNO is denitrosylated by GSNO reductase (GSNOR), the SNO formed by low-molecular-mass thiols could also transnitrosylate some other proteins, in which case the overall protein SNO will not change.
Compared to transnitrosylation, protein denitrosylation plays an important role in eliminating SNO proteins therefore regulating cellular SNO levels. Some enzymatic systems have been shown to function as denitrosylase, such as GSNOR, 97, 98 the thioredoxin system, 99 carbonyl reductase, 100 Cu, Znsuperoxide dismutase, 101 and xanthine oxidoreductase. 102 Their physiological role as a critical regulator of SNO biology has been discussed in detail elsewhere. 103, 104 Given that these denitrosylases are coupled to cellular antioxidant redox enzymatic systems, the level of protein S-nitrosylation will be regulated by cellular redox state. Cellular redox changes during ischemia and reperfusion and this is likely to have important effects on protein SNO.
Detection of S-Nitrosylated Protein
Most methods used to detect S-nitrosylated proteins are based on the biotin switch method. 105 Briefly in the biotin switch method, free thiol groups are blocked with a methyl methylating agent, the SNO groups are then reduced with ascorbate to free thiol groups that are then labeled with a sulfhydryl specific biotinylating agent. In this way, the proteins that were originally S-nitrosylated are now labeled with a biotin and can be detected with an anti-biotin antibody. As is the case with any protein identification strategy, the set of SNO proteins that are detected depends to some extent on the details of the method used. For example, if one were attempting to determine what proteins were phosphorylated by cardioprotection, one might use different methods. Typically one would test for a specific pathway using a specific antibody such as an antibody that recognizes phospho-AKT, for example. Therefore, to use a similar approach to detect SNO proteins following the biotin switch, one could immunoprecipitate with antibodies for specific proteins and then immunoblot with anti-biotin to determine whether the protein is S-nitrosylated. Another approach used to detect phosphorylated proteins in cardioprotection is to run a gel and then blot with an anti-phosphoserine/threonine or anti-phosphotyrosine antibody. Analogous to this, after the biotin-switch method, one could run the entire extract on a gel and probe with an anti-biotin antibody. Anti-SNO-specific antibodies (analogous to anti-phospho antibodies) are available and are currently being compared to results obtained with the biotin switch. Recently the use of 2D gel electrophoresis methods and mass spectrometry has been applied to identify phosphorylated proteins in cardioprotection. 106 A similar approach can also be used to measure protein SNO. 31, 47, 107 As is the case with phosphorylation, these different methods can result in the identification of many proteins. Although 2D gel methods provide unbiased information on a large number of proteins, high-molecular-weight and membrane proteins do not readily enter the 2D gel and are therefore often undetected with 2D methods. 108 Also, because of dynamic range issues, most of the proteomic methods (2D gels and mass spectrometry) are biased toward detection of high-abundance proteins. Thus, lack of detection of a low-abundance protein in a 2D gel or mass spectrometric analysis does not mean that the protein is not subjected to SNO modification. To date, many of the studies identifying SNO proteins have used 2D gels, and, therefore, there are likely to be many low-abundance signaling molecules, which are S-nitrosylated, that have not been currently identified. It should also be mentioned that in assessing the effect of a treatment on SNO, it is important to normalize the change in SNO to total protein, similar to what is routinely done in the evaluation of phosphorylation. SNO content can be detected and quantified by colorimetric (HgCl 2 -coupled Griess reagent), chemiluminescent (Ozonecoupled photolysis), fluorescent methods (4,5-diaminofluorescein), and anti-S-nitrosocysteine-based methods.
SNO and Cardioprotection Cardioprotection Results in SNO of Many Common Proteins
Although NO is clearly established as a mediator of cardioprotection, there have been only a few studies that have examined the role of protein S-nitrosylation in cardioprotection. PC has been shown to result in S-nitrosylation of a number of proteins, 31 as might be expected given the increase of NO formation in PC. Interestingly, although postconditioning and delayed PC both require NO, protein S-nitrosylation has not been examined under these conditions. NO donors such as GSNO have been shown to also increase S-nitrosylation of a number of proteins, many of which overlap with proteins undergoing S-nitrosylation during PC. 31 Estrogen has also been shown to be cardioprotective and it results in the S-nitrosylation of many proteins in common with PC and GSNO. 47 A recent study has shown that mice lacking GSNOR, an enzyme involved in removing SNO from proteins, results in increased protein SNO and cardioprotection. 97 Thus, considerable evidence is accumulating suggesting that an increase in SNO is associated with cardioprotection.
The Table lists a number of proteins that have been reported to show a change in SNO with different cardioprotective treatments. In this Table, we have focused on acute protection in cardiomyocytes. An interesting general observation is that many of the proteins showing increased S-nitrosylation with cardioprotection are mitochondrial proteins. Possible reasons for this include the increased stability of N 2 O 3 in the hydrophobic milieu of the mitochondria, which would favor S-nitrosylation, and the high level of reactive cysteines in mitochondrial proteins. 109, 110 Because NO is labile, the high level of SNO of mitochondrial proteins suggests a nearby source of NO, such as the endoplasmic/ sarcoplasmic reticulum as discussed previously. In addition, protein S-nitrosylation in mitochondria can occur as a result of transnitrosylation from low-molecular-mass SNO, such as GSNO. 94 As mentioned earlier, low-abundance signaling proteins are not well represented in the 2D proteomic screens that have been largely used to identify S-nitrosylated protein by cardioprotective treatments. Thus, it is very likely that there are other SNO proteins, some of which have not yet been identified, that play a role in cardioprotection. For example, PTEN (phosphatase and tensin homolog deleted on chromosome 10) has been reported to be inhibited by S-nitrosylation, 111, 112 and inhibition of PTEN would be expected to increase signaling through the phosphatidylinositol 3-kinase pathway, a pathway that has been shown to initiate cardioprotection. [113] [114] [115] S-Nitrosylation of PTEN has not been observed in heart in cardioprotection, but this might just reflect the low abundance of PTEN, which might be difficult to detect with 2D screening methods. Much additional work will be needed to fully elucidate the mechanism by which SNO modulates cardioprotection.
Is SNO an Epiphenomena or Involved in Protection?
Consistent with a role for NO/SNO in protection, L-NAME blocks both the protection and SNO generation that are mediated by preconditioning or treatment with an estrogen agonist. 47 Furthermore, the finding that loss of GSNOR is cardioprotective supports a protective role for SNO. 97 However, to clearly establish the importance of S-nitrosylation of any protein or class of proteins in protection, it will be necessary to mutate the thiols that are S-nitrosylated and determine whether this blocks protection. One of the challenges is that many proteins are S-nitrosylated in PC and other models of cardioprotection. Are one or a few of these proteins causally involved or are many or all important? If S-nitrosylation of multiple proteins and/or pathways is necessary, it may be difficult to sort out which proteins are important using a mutation strategy for a single protein. Also, it is likely that SNO can have beneficial and detrimental effects and that cardioprotection depends on the balance.
Possible Mechanism(s) for SNO-Mediated Cardioprotection: General Mechanisms
The Table shows a large and growing list of proteins that are S-nitrosylated in the setting of cardioprotection. How might S-nitrosylation of these proteins lead to reduced cell death? Analogous to phosphorylation, S-nitrosylation can alter the activity of proteins. In addition to modulating the activity of proteins, it has been suggested that S-nitrosylation, either directly or by enhancing S-glutathionylation, can also protect reactive thiol groups from more irreversible oxidation, thereby allowing the activity of these enzyme to be restored more quickly following oxidative stress as might occur during I/R. 116,117 S-Nitrosylation not only modifies proteins, leading to altered activity and protection against further oxidation, but can also facilitate additional posttranslational modifications such as S-glutathionylation, which can alter protein activity. 117, 118 As discussed by Baba et al, the S-nitrosylated form of aldose reductase, but not the reduced form, can react with GSH to form S-glutathionylated aldose reductase and increase its activity. 118 
S-Nitrosylation Alters Protein Activity
S-Nitrosylation of the mitochondrial complex I, 31, 64, 119 cytochrome c oxidase, 120 the F1F0ATPase (complex V), 31 and creatine kinase 121 inhibit their activities, whereas S-nitrosylation of ␣-ketoglutarate dehydrogenase increases its activity. 31 S-Nitrosylation of the L-type Ca 2ϩ channel has been reported to reduce the channel activity in the hearts under adrenergic stimulation, 11 under oxidative stress during PC, 31 and with atrial fibrillation. 122 S-Nitrosylation of the cardiac SR calcium release channel/ryanodine receptor (RyR2) has been shown to increase its open channel probability. Also the decreased S-nitrosylation of RyR2 in nNOS-KO hearts has been suggested to cause cysteine residues of RyR2 to be more oxidized under oxidative stress, leading to SR Ca 2ϩ leakage and arrhythmogenesis. 123 Cardiac SR Ca 2ϩ -ATPase (SERCA2a) has also been shown to be activated by an NO-dependent modification. Adachi et al showed that NOdependent S-glutathionylation (occurring via peroxynitrite and therefore dependent on superoxide generation as well as NO and GSH) of SERCA2a resulted in an increase in SERCA2a activity. 124 Sun et al also found S-nitrosylation of SERCA2a was associated with increased SR Ca 2ϩ -ATPase activity in PC hearts. 31 However, whether S-nitrosylation of SERCA2a per se increases activity or whether S-nitrosylation increases SERCA2a activity by enhancing S-glutathionylation remains to be sorted out.
Protein S-nitrosylation has also shown to play an important cardioprotective role by modulating the activity of proteins involved in apoptosis and oxidative stress such as caspase 3, 125 cyclooxygenase-2, 126 hypoxia inducible factor 1␣, 97 NADPH oxidase, 127 and thioredoxin. 128 Furthermore, recent studies suggest that NOS generates NO locally and regulates compartmentalized S-nitrosylation and protein trafficking in the cardiovascular system. 129 135 have been identified to be S-nitrosylated and S-nitrosylation of these proteins play an important role in regulating protein trafficking and signaling transduction. Figure 1 provides a potential mechanism(s) by which protein S-nitrosylation might lead to acute protection as occurs in PC. PC results in S-nitrosylation and inhibition of the L-type Ca 2ϩ channel, which would reduce Ca 2ϩ entry into the myocytes during ischemia and early reperfusion. S-Nitrosylation (by itself or by promoting S-glutathionylation) also results in activation of SERCA2a, which would further reduce cytosolic Ca 2ϩ during ischemia and early reperfusion. In fact, enhanced expression of SERCA2a has been shown to be cardioprotective. 136 PC also results in S-nitrosylation and inhibition of the F1F0ATPase which would reduce ATP consumption by reverse mode of the F1F0ATPase. 31 This would preserve ATP and would also reduce the mitochondrial membrane potential (⌬), thereby reducing the driving force for Ca 2ϩ uptake into the mitochondrial matrix. PC has also been shown to lead to S-nitrosylation and inhibition of complex I, which has been suggested to reduce ROS generation. 64, 119 Taken together, the increase of protein S-nitrosylation during PC would be expected to lead to reduced mitochondrial Ca 2ϩ and reduced ROS generation, which together would be expected to prevent the mitochondrial permeability transition pore opening and reduce cell death, because mitochondrial permeability transition pore opening has been shown to be an important determinant of myocardial I/R death. 137, 138 SNO Enhances S-Glutathionylation S-Nitrosylation can also enhance the addition of glutathione to proteins through a modification known as S-glutathionylation. 117, 118 Similar to S-nitrosylation, S-glutathionylation can alter protein activity and protect cysteines from irreversible oxidation. 117, 139 For example, aldose reductase activity is increased by S-glutathionylation, 118 and S-glutathionylation of complex II has also been shown to enhance electron transfer. 140 Interestingly, S-glutathionylation of complex II is decreased during reperfusion following ischemia 140 ; it might be interesting to determine whether cardioprotection reverses this loss of S-glutathionylation. S-Glutathionylation can be reversed following the restoration of a reducing GSH/oxidized glutathione ratio. However, S-glutathionylation can also lead to irreversible protein posttranslational modification under excessive oxidative and nitrosative stress. 139 
SNO Protects Against Irreversible Oxidation
The modification of thiols can be regulated by redox-related signaling in the cell including ROS/reactive nitrogen species. 3 In addition to S-nitrosylation and S-glutathionylation, free thiols can be oxidized to sulfenic acid (SOH), sulfinic acid (SO 2 H), disulfide bonds, or sulfonic acid (SO 3 H). With increasing oxidation states, the modifications become irreversible and this typically leads to irreversible modification of the protein. 24, 141 It has been suggested that S-nitrosylation and S-glutathionylation of thiol groups in proteins can protect these proteins against irreversible oxidative modifications. 116, 117, 142 Furthermore, irreversible oxidation of thiols can block the physiological modification by S-nitrosylation or S-glutathionylation and thereby interfere with normal physiological signaling. 124 An example of how S-nitrosylation can protect against irreversible oxidation of a protein is provided by studies on protein-tyrosine phosphatase. 143 The activity of proteintyrosine phosphatase can be regulated by thiol redox modification at an active cysteine residue, which is also susceptible to S-nitrosylation. A recent study revealed that the active site cysteine 215 was the primary cysteine residue susceptible to S-nitrosylation, and the S-nitrosylation at cysteine 215 protects protein-tyrosine phosphatase from subsequent irreversible oxidation. Thus, S-nitrosylation of cysteine 215 might prevent protein-tyrosine phosphatase from permanent inactivation caused by oxidative stress. 143 It is suggested that S-nitrosylation might form a reversible "molecular shield" that prevents further thiol oxidation during excessive oxidative/nitrosative stress. 116 S-Nitrosylation can also control cellular redox through the regulation of some important redox-active enzymes, such as GSNOR, 97, 98 thioredoxin, 144 -146 glutaredoxin, 147 peroxiredoxin 148 and their corresponding reductase system. It has been suggested that NO can protect cells from oxidative stress, whereas loss or inhibition of NOS enhances oxidative stress. 123, 149 Possible Role of S-Nitrosylation in Explaining Discrepant Effects of NO As mentioned earlier, with high levels of NO or an increase in the ratio of ROS to NO the beneficial effects of NO are lost and NO can have detrimental effects. The variability in the channel, which would reduce Ca 2ϩ entry into the myocyte during ischemia and early reperfusion. S-Nitrosylation also results in activation of SERCA2a, thus further reducing cytosolic Ca 2ϩ during ischemia and early reperfusion. PC also results in S-nitrosylation and inhibition of the F1F0ATPase, which would reduce ATP consumption by reverse mode of the F1F0ATPase. PC has also been shown to lead to S-nitrosylation and inhibition of complex I, which has been suggested to reduce ROS generation. Taken together, the increase of protein S-nitrosylation during PC would be expected to lead to reduced Ca 2ϩ overload and reduced ROS generation, therefore preventing cell death during I/R injury.
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amount of ROS might explain some of the discrepant findings in the literature. As just discussed, S-nitrosylation of several proteins might reduce production of ROS during ischemia and early reperfusion, which in turn would reduce peroxynitrite generation and might contribute to the beneficial effects of NO. Thus, it is possible that the depending on the levels of NO generation and ROS generation different proteins might be S-nitrosylated and this might alter the balance between cell protection and cell death.
Timing of S-Nitrosylation and Denitrosylation
Protein S-nitrosylation is a very labile modification, and it appears that SNO-mediated cardioprotection induced by PC has a very short duration. This would be an ideal property for a cardioprotective signal. For example, long-term inhibition of the F1F0ATPase or complex I would likely have detrimental consequences. However, it appears that SNO is reversed early during reperfusion. Thus, SNO can modify activity of these proteins during ischemia and the start of reperfusion, but then with the loss of SNO during early reperfusion, the activity of these proteins returns to normal. The lability of SNO might also account for the loss of PC when the period between the PC and the sustained ischemia is extended.
Does Protection Depend on the Level of SNO?
The scenario proposed in Figure 1 and data in several studies 31, 47, 97, 119 suggest that cardioprotection is associated with an increase in SNO. Although a general increase in SNO appears to be associated with cardioprotection, it is likely an oversimplification to assume that S-nitrosylation of all proteins is cardioprotective. If one considers phosphorylation, depending on the target, phosphorylation can stimulate cell death, as well as protection, and therefore it is likely that S-nitrosylation can mediate cell death, as well as protection. For example, GAPDH, a protein involved in glycolysis, which has recently been shown to have an additional function in regulating cell death, has been reported to initiate a cell death pathway in neurons. 150 S-Nitrosylation of GAPDH enhances its binding to Siah1 (seven in absentia homolog 1, an E3 ubiquitin ligase) and mediates its translocation to the nucleus and the initiation of cell death. Interestingly Sen et al have reported that GOSPEL (GAPDH competitor of Siah protein enhances life), a protein that competes with GAPDH for binding to Siah, is also S-nitrosylated. 151 S-Nitrosylation of GOSPEL promotes the binding of GOSPEL to GAPDH, which reduces GAPDH binding to Siah1 thus preventing neuronal cell injury and death. 151 Thus, it is proposed that an NO/SNO signaling will lead to S-nitrosylation of different proteins depending on the level of SNO generation or the activation of other signaling pathways. It will be important in future studies to identify (as in the case of GAPDH and GOSPEL) the details of the pathways by which SNO regulates protection as well as death. Therefore, it is likely that S-nitrosylation of some proteins will promote rather than inhibit cell death, and the outcome depends on the balance. We are just beginning to understand the complex relationship between SNO, cell death, and cardioprotection. Similar to phosphorylation, SNO signaling is compartmentalized. There is also likely to be crosstalk with other signaling pathways such as redox and phosphorylation, and ROS/reactive nitrogen species have been suggested to alter the balance between phosphorylation and S-nitrosylation of key signaling molecules. 1, 3, 152 The association between increased SNO and cardioprotection 31, 47, 97, 119 might suggest that under these cardioprotective conditions the beneficial effects of SNO predominate over the detrimental effects.
Conclusion and Future Perspective
Protein S-nitrosylation, a reversible, redox-sensitive, thiolbased posttranslational modification, has been found to play an important role in a wide range of NO-mediated cardiovascular effects, including but not limited to mitochondrial metabolic regulation, intracellular Ca 2ϩ handling, protein trafficking, and regulation of cellular defense against apoptosis and oxidative stress. As shown in Figure 2 , S-nitrosylated proteins could elicit their regulatory effects and protect cells by (1) changing the structure and function of proteins because of SNO modification on the active thiol(s) and (2) shielding the modified cysteine residues (by S-nitrosylation or S-glutathionylation) from further irreversible modification under oxidative/nitrosative stress. Furthermore, depending on the localization of NO/SNO signaling, the level of protein S-nitrosylation, and/or interaction with other signaling pathways, the overall effect of protein S-nitrosylation can be protective or detrimental (eg, GOSPEL/GAPDH). The feasibility of pharmacological preconditioning with SNO has provided an intriguing therapeutic strategy for protecting against myocardial I/R injury. 69, 97, [153] [154] [155] Taken together, protein S-nitrosylation and S-nitrosylated proteins have emerged as an important contributor to cardioprotection.
There are a number of important areas for future studies. It has been proposed that S-nitrosylation of cysteine residues might protect them from oxidation. It will be important to determine exactly which proteins and cysteine residues are S-nitrosylated under cardioprotection which would otherwise be oxidized. It will also be important to better understand the relationship between redox, ROS levels, NO levels, and protection. As discussed, S-nitrosylation of some proteins will be beneficial, whereas S-nitrosylation of others will be detrimental. It will be important to understand how S-nitrosylation of different proteins is regulated. Is the S-nitrosylation of different proteins controls solely by varying the amount of NO (probably not this simple)? We know there is localization of NOS and this likely contributes to the differences in protein S-nitrosylation. There are also subcellular differences in enzymes that denitrosylate proteins, and this will also contribute to the regulation of compartmentalized subcellular SNO signaling. The past decade has provided a wealth of new information on how SNO modifies cell biology, but we have only just begun!
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